Efficacy and safety of artemether-lumefantrine for the treatment of uncomplicated malaria and prevalence of Pfk13 and Pfmdr1 polymorphisms after a decade of using artemisinin-based combination therapy in mainland Tanzania.
Celine I MandaraCeline I MandaraFilbert FrancisEldin TalundzicNaomi W LucchiBilly NgasalaAbdunoor M KabanywanyiMuhidin K MahendeErasmus KamugishaReginald A KavisheFlorida MuroAlly MohamedRenata MandikeSigsbert MkudeFrank ChackyLynn PaxtonGeorge GreerChonge A KitojoRitha NjauTroy MartinMeera VenkatesanMarian WarsameEric S HalseyVenkatachalam UdhayakumarPublished in: Malaria journal (2019)
The study indicated high efficacy of AL and the safety profile was consistent with previous reports. There were no known artemisinin-resistance Pfk13 mutations, but there was a high prevalence of a Pfmdr1 haplotype associated with reduced sensitivity to lumefantrine (but no reduced efficacy was observed in the subjects). Continued TES and monitoring of markers of resistance to artemisinin and partner drugs is critical for early detection of resistant parasites and to inform evidence-based malaria treatment policies. Trial Registration ClinicalTrials.gov NCT03387631.